Lucitanib for Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Posted: Tuesday, January 8, 2019
Lucitanib seems to provide antitumor activity in patients with hormone receptor–positive, HER2-negative metastatic breast cancer by inhibiting the fibroblast growth factor receptor-1 (FGFR1) gene. The FGFR1 gene is amplified in about 15% of this patient population. Findings from the multicohort phase II FINESSE trial were presented by Rina Hui, MBBS, FRACP, PhD, of the Crown Princess Mary Cancer Centre in Westmead, Australia, and colleagues at the European Society for Medical Oncology (ESMO) 2018 Congress (Abstract 289PD).
Of 76 patients with hormone receptor–positive, HER2-negative metastatic breast cancer, 32 were considered to have FGFR1-amplified disease, 18 had FGFR1-nonamplified, 11q13-amplified disease, and 26 had FGFR1 and 11q13 nonamplified disease. These patients had received at least one line and no more than two lines of chemotherapy.
The overall response rate to oral lucitanib was 19% for the FGFR1-amplified chort, 0% for the FGFR1 nonamplified, 11q13-amplified cohort, and 15% for the FGFR1 and 11q13 nonamplified cohort. The complete response, partial response, and stable disease rates after 24 weeks were 41%, 11%, and 27%, respectively. The overall response rate in those with high FGFR1-amplified disease (FGFR1/centromere ratio > 4) was 25% compared with 8% in those with low FGFR1-amplified cancers. Progression-free survival for the 20 patients with FGFR1 membrane overexpression was, on average, 3 months longer than that for other patients. Adverse effects included grade > 3 hypertension, hypothyroidism, nausea, and proteinuria.
“Biomarker analyses generate the hypothesis that patients with high FGFR1 expression could derive more benefit,” the investigators concluded. “This population deserves further exploration in a large trial.”
Disclosure: The study authors’ disclosure information may be found at cslide.ctimeetingtech.com.